Psoriasis and psoriatic arthritis are common diseases with significant physical 
and emotional burden. Several biologics are FDA-approved to treat psoriasis and 
psoriatic arthritis, though some patients remain refractory to, or have lost 
response to, therapy and/or cannot tolerate the associated risks and side 
effects. Bimekizumab is a new biologic that inhibits both IL-17A and IL-17F. It 
is currently in phase III clinical trials. To date, phase II studies show 
promise in its ability to rapidly resolve symptoms while remaining safe and 
well-tolerated. Areas covered: This review serves to summarize the literature 
regarding the use of bimekizumab for psoriasis and psoriatic arthritis. 
Bimekizumab has undergone phase I and phase II clinical trials with results 
showing significant disease improvement or resolution, as well as safety and 
tolerability. Phase III studies are now actively enrolling. Expert opinion: 
Bimekizumab is a burgeoning biologic offering significant promise through its 
unique bispecific targeting of both IL-17A and IL-17F. Clinical trials have 
shown the potential of rapid symptom improvement after treatment with 
bimekizumab, with some patients seeing improvement after only two weeks. To 
date, bimekizumab has been shown to be safe and well-tolerated by patients, 
without any associated significant adverse events.